Publications

BibTex format

@article{Feng:2021:10.1038/s41591-021-01540-1,
author = {Feng, S and Phillips, DJ and White, T and Sayal, H and Aley, PK and Bibi, S and Dold, C and Fuskova, M and Gilbert, SC and Hirsch, I and Humphries, HE and Jepson, B and Kelly, EJ and Plested, E and Shoemaker, K and Thomas, KM and Vekemans, J and Villafana, TL and Lambe, T and Pollard, AJ and Voysey, M and Adlou, S and Allen, L and Angus, B and Anslow, R and Asselin, M-C and Baker, N and Baker, P and Barlow, T and Beveridge, A and Bewley, KR and Brown, P and Brunt, E and Buttigieg, KR and Camara, S and Charlton, S and Chiplin, E and Cicconi, P and Clutterbuck, EA and Collins, AM and Coombes, NS and Clemens, SAC and Davison, M and Demissie, T and Dinesh, T and Douglas, AD and Duncan, CJA and Emary, KRW and Ewer, KJ and Felle, S and Ferreira, DM and Finn, A and Folegatti, PM and Fothergill, R and Fraser, S and Garlant, H and Gatcombe, L and Godwin, KJ and Goodman, AL and Green, CA and Hallis, B and Hart, TC and Heath, PT and Hill, H and Hill, AVS and Jenkin, D and Kasanyinga, M and Kerrid},
doi = {10.1038/s41591-021-01540-1},
journal = {Nature Medicine},
pages = {2032--2040},
title = {Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection},
url = {http://dx.doi.org/10.1038/s41591-021-01540-1},
volume = {27},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF50) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymptomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines.
AU  - Feng,S
AU  - Phillips,DJ
AU  - White,T
AU  - Sayal,H
AU  - Aley,PK
AU  - Bibi,S
AU  - Dold,C
AU  - Fuskova,M
AU  - Gilbert,SC
AU  - Hirsch,I
AU  - Humphries,HE
AU  - Jepson,B
AU  - Kelly,EJ
AU  - Plested,E
AU  - Shoemaker,K
AU  - Thomas,KM
AU  - Vekemans,J
AU  - Villafana,TL
AU  - Lambe,T
AU  - Pollard,AJ
AU  - Voysey,M
AU  - Adlou,S
AU  - Allen,L
AU  - Angus,B
AU  - Anslow,R
AU  - Asselin,M-C
AU  - Baker,N
AU  - Baker,P
AU  - Barlow,T
AU  - Beveridge,A
AU  - Bewley,KR
AU  - Brown,P
AU  - Brunt,E
AU  - Buttigieg,KR
AU  - Camara,S
AU  - Charlton,S
AU  - Chiplin,E
AU  - Cicconi,P
AU  - Clutterbuck,EA
AU  - Collins,AM
AU  - Coombes,NS
AU  - Clemens,SAC
AU  - Davison,M
AU  - Demissie,T
AU  - Dinesh,T
AU  - Douglas,AD
AU  - Duncan,CJA
AU  - Emary,KRW
AU  - Ewer,KJ
AU  - Felle,S
AU  - Ferreira,DM
AU  - Finn,A
AU  - Folegatti,PM
AU  - Fothergill,R
AU  - Fraser,S
AU  - Garlant,H
AU  - Gatcombe,L
AU  - Godwin,KJ
AU  - Goodman,AL
AU  - Green,CA
AU  - Hallis,B
AU  - Hart,TC
AU  - Heath,PT
AU  - Hill,H
AU  - Hill,AVS
AU  - Jenkin,D
AU  - Kasanyinga,M
AU  - Kerridge,S
AU  - Knight,C
AU  - Leung,S
AU  - Libri,V
AU  - Lillie,PJ
AU  - Marinou,S
AU  - McGlashan,J
AU  - McGregor,AC
AU  - McInroy,L
AU  - Minassian,AM
AU  - Mujadidi,YF
AU  - Penn,EJ
AU  - Petropoulos,CJ
AU  - Pollock,KM
AU  - Proud,PC
AU  - Provstgaard-Morys,S
AU  - Rajapaska,D
AU  - Ramasamy,MN
AU  - Sanders,K
AU  - Shaik,I
AU  - Singh,N
AU  - Smith,A
AU  - Snape,MD
AU  - Song,R
AU  - Shrestha,S
AU  - Sutherland,RK
AU  - Thomson,EC
AU  - Turner,DPJ
AU  - Webb-Bridges,A
AU  - Wrin,T
AU  - Williams,CJ
DO  - 10.1038/s41591-021-01540-1
EP  - 2040
PY  - 2021///
SN  - 1078-8956
SP  - 2032
TI  - Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
T2  - Nature Medicine
UR  - http://dx.doi.org/10.1038/s41591-021-01540-1
UR  - https://www.nature.com/articles/s41591-021-01540-1
UR  - http://hdl.handle.net/10044/1/91827
VL  - 27
ER  -

Download

DrVincenzoLibri

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)